Renal and Metabolic Clearance of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in Humans

Hypertension - United States
doi 10.1161/01.hyp.33.3.879
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: A Valuable Endogenous Anti-Fibrotic Peptide for Combating Kidney Fibrosis in Diabetes

Frontiers in Pharmacology
Pharmacology
2014English

Combination Treatment With N-Acetyl-Seryl-Aspartyl-Lysyl-Proline and Tissue Plasminogen Activator Provides Potent Neuroprotection in Rats After Stroke

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2014English

Scientific Letter: Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) and Galectin-3 Levels in Tuberculous Pericardial Effusion: Implications for Pathogenesis and Prevention of Pericardial Constriction

Heart
Cardiovascular MedicineCardiology
2012English

Converting Enzyme Inhibition and Renal Tissue Angiotensin II in the Rat

Hypertension
Internal Medicine
1994English

Cough and Angiotensin Converting Enzyme Inhibition

BMJ
1988English

Points: Cough and Angiotensin Converting Enzyme Inhibition

BMJ
1988English

Drug Points: Irreversible Renal Transplant Failure After Angiotensin Converting Enzyme Inhibition

BMJ
1986English

Inhibition of Angiotensin Converting Enzyme by Mushroom

Nippon Shokuhin Kagaku Kogaku Kaishi
Food Science
2006English

Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP

Hypertension
Internal Medicine
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy